Featured Story | | | Wednesday, August 23, 2017 Shares in Paratek were up almost a third in premarket trading this morning after Bloomberg said the company, gearing up to file a new antibiotic, is considering a sale. |
|
|
| This week's sponsor is FierceBiotech Drug Development Forum. | |  | Save 15% on the FierceBiotech 2nd Drug Development Forum
Network with 300+ biotech leaders and 90+ executive-level speakers at the largest biotech conference for optimizing pipeline strategies, partnerships and deal making September 25-27 in Boston, MA. Sign up today & save 15% w/ code C942FIERCE. |
Top Stories Wednesday, August 23, 2017 Ultragenyx has given muscle disease candidate Ace-ER the heave-ho after it failed in phase 3. The GNE myopathy trial missed its primary endpoint and all key secondary endpoints, delivering a blow to Ultragenyx as it enters a critical period for its prospects. Wednesday, August 23, 2017 Longevity Fund has raised $22 million to make a fresh wave of investments in companies working to treat age-related diseases. The financing positions Laura Deming, the prodigy who started work on the fund before turning 18, to follow up on the bets she has already placed on companies such as Unity Biotechnology. Wednesday, August 23, 2017 San Diego cancer biotech MabVax Therapeutics is hiring an investment bank to help it find a buyer or sell off its assets as it continues to struggle for cash. Tuesday, August 22, 2017 Former 23andMe President Andy Page will join Livongo Health, a digital health company focused on chronic disease, as its president and chief financial officer. Wednesday, August 23, 2017 Healthcare IT platform provider Allscripts has partnered with Elligo Health Research to help improve clinical trial enrollment by helping physicians conduct clinical studies in their own clinics. The offering will be available to Allscripts' EHR system customers. Wednesday, August 23, 2017 Novartis has launched plenty of large-scale multiple sclerosis studies. But its newest one is different. The latest, dubbed elevateMS, allows participants to contribute no matter where they are by using their smartphones and an app developed for the purpose. | This week's sponsor is FierceBiotech. | |  | FierceBiotech Executive Summit- London
Join FierceBiotech for our third annual Executive Summit in London. We'll gather the experts together to discuss innovation around R&D in the UK and look ahead to what's in store for 2018 with leaders in the field discussing trends in the industry. |
Resources Sponsored by: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Presented By: MPI Research FierceBiotech interviews Dr. DeWit to discuss a common cause for drug development delays, and strategies to avoid these costly setbacks. Sponsored by: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored by: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. | 
